Potential nanotherapeutic strategies for perioperative stroke

An, Jing; Zhao, Ling; Duan, Ranran; Sun, Ke; Lu, Wenxin; Yang, Jiali; Liang, Yan; Liu, Junjie; Zhang, Zhenzhong; Li, Li; Shi, Jinjin

doi:10.1111/cns.13819

Cited by 4 publications

(4 citation statements)

References 109 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…An individualized treatment approach is recommended based on types of malignancies and stroke severities. [90][91][92][93] Moreover, MAS patients with Trousseau syndrome typically have poor survival. Therefore, there is a need to determine the effectiveness of rehabilitation treatment and develop a comprehensive treatment strategy earlier than that in the general stroke population.…”

Section: F I G U R Ementioning

confidence: 99%

“…An individualized treatment approach is recommended based on types of malignancies and stroke severities. 90 , 91 , 92 , 93 …”

Section: Therapeutic Options For Mas Patientsmentioning

confidence: 99%

“…However, additional large, randomized trials are required to address relevant questions of intervention safety and efficacy. An individualized treatment approach is recommended based on types of malignancies and stroke severities 90–93 …”

Section: Therapeutic Options For Mas Patientsmentioning

confidence: 99%

See 2 more Smart Citations

Malignancy‐associated ischemic stroke: Implications for diagnostic and therapeutic workup

Xie,

Hsu,

Lin

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

BackgroundPatients with malignancies have an increased risk of suffering ischemic stroke via several mechanisms such as coagulation dysfunction and other malignancy‐related effects as well as iatrogenic causes. Moreover, stroke can be the first sign of an occult malignancy, termed as malignancy‐associated ischemic stroke (MAS). Therefore, timely diagnostic assessment and targeted management of this complex clinical situation are critical.FindingsPatients with both stroke and malignancy have atypical ages, risk factors, and often exhibit malignancy‐related symptoms and multiple lesions on neuroimaging. New biomarkers such as eicosapentaenoic acid and blood mRNA profiles may help in distinguishing MAS from other strokes. In terms of treatment, malignancy should not be considered a contraindication, given comparable rates of recanalization and complications between stroke patients with or without malignancies.ConclusionIn this review, we summarize the latest developments in diagnosing and managing MAS, especially stroke with occult malignancies, and provide new recommendations from recently emerged clinical evidence for diagnostic and therapeutic workup strategies.

show abstract

Section: F I G U R Ementioning

confidence: 99%

“…An individualized treatment approach is recommended based on types of malignancies and stroke severities. 90 , 91 , 92 , 93 …”

Section: Therapeutic Options For Mas Patientsmentioning

confidence: 99%

See 1 more Smart Citation

Malignancy‐associated ischemic stroke: Implications for diagnostic and therapeutic workup

Xie,

Hsu,

Lin

et al. 2024

CNS Neurosci Ther

View full text Add to dashboard Cite

show abstract

“…These include using gases (such as hydrogen, argon, or xenon), pharmaceuticals (eg, nerinetide to counteract oxidative stress), immune or stem cell therapies (Treg and mesenchymal lymphocytes or neural stem cells, respectively) and the use of preconditioning or follow-up procedures [ 22 ]. The hope in therapy is also to use the possibilities of nanotechnology, which makes it possible to use nanoparticles as nanocarriers to precisely deliver drugs with revascularization, anti-inflammatory, neuroregenerative, or anti-reactive oxygen species effects to brain tissue [ 28 ].…”

Section: Perioperative Stroke (Pos) After General Anesthesiamentioning

confidence: 99%

Decoding the Neurological Sequelae of General Anesthesia: A Review

Radkowski,

Oniszczuk,

Fadrowska-Szleper

et al. 2023

Med Sci Monit

View full text Add to dashboard Cite

General anesthesia is an integral part of modern surgical practice, but it is associated with a number of complications, including neurological ones. This article provides a thorough analysis of these complications, taking into account the most common ones like drug complications, through delirium, postoperative cognitive impairment (POCD), to the rarest ones like perioperative stroke (POS), spinal cord ischemia (SCI), and postoperative visual loss (POVL). Its main goal is to familiarize healthcare professionals, especially those involved in anesthesiology, with the intricacies of neurological complications. Given their specificity and frequency of occurrence, it is well known that the diagnosis and management of these complications can sometimes cause problems for physicians without advanced neurological knowledge. Also, in addition to complex diagnostics, the pathomechanism of non-pharmacological complications is often not fully understood due to their multifactoriality and sometimes paucity of research. For this reason, an increasing amount of work is being done in the medical community to better understand this group of conditions, enabling faster diagnosis and more effective treatment, as well as perioperative prevention. This paper aims to increase awareness and vigilance among physicians across the spectrum of surgical patient care, from premedication to postoperative follow-up. Drawing on the authors’ experience and the extensive medical literature, this paper includes 39 selected articles from 1994 to 2023, seeking the latest insights in the constantly evolving field of neurology and anesthesiology. This article aims to review the neurological complications of general anesthesia.

show abstract